CCO Oncology Podcast
About
Available on
Community
168 episodes
In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: __ __ Presenters: HEATHER H. CHENG, MD, PHD Associate Professor Department of Medicine Division of Hematology and Oncology Attending Physician Department of Genitourinary Medical Oncology Fred Hutchinson Cancer Center Seattle, Washington COLIN C. PRITCHARD, MD, PHD Co-Director Genetics and Solid Tumors Laboratory University of Washington Medical Center Professor Department of Laboratory Medicine and Pathology University of Washington Seattle, Washington Content based on an online CME program supported by an independent educational grant from Pfizer, Inc. Link to full program: https://bit.ly/3PFagxb
In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including: __ __ Presenters: SARA M. TOLANEY, MD, MPH Chief, Division of Breast Oncology Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts MELINDA TELLI, MD Professor of Medicine Stanford University School of Medicine Director, Breast Cancer Program Stanford Cancer Institute Palo Alto, California Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc. Link to full program: https://bit.ly/49WxRBM
The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer. PRESENTERS IN THIS SERIES INCLUDE: REBECCA S. HEIST, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts HELENA YU, MD Associate Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Supported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including a downloadable highlights slideset: https://bit.ly/48ecElW
This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including: __ __ PRESENTERS IN THIS SERIES INCLUDE: REBECCA S. HEIST, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts HELENA YU, MD Associate Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Supported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including a downloadable highlights slideset: https://bit.ly/48ecElW
This first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs. PRESENTERS IN THIS SERIES INCLUDE: REBECCA S. HEIST, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts HELENA YU, MD Associate Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Supported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including a downloadable highlights slideset: https://bit.ly/48ecElW
In this episode, Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, share their thoughts and opinions on seminal data presented at the 2023 IGCS annual meeting for endometrial, ovarian, and cervical cancers, including: __ __ PRESENTERS: BRIAN SLOMOVITZ, MD, MS, FACOG Director Gynecologic Oncology Mount Sinai Medical Center Professor Obsterics and Gynecology Florida International University Member, Board of Directors GOG Foundation Uterine Cancer Lead GOG Partners Miami, Florida KEIICHI FUJIWARA, MD, PHD Professor of Gynecologic Oncology Saitama Medical University International Medical Center Hidaka, Japan Professor of OBGYN International University of Health and Welfare Narita, Japan This educational activity is supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, and Seagen. Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries: https://bit.ly/424E3Uq
In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including: __ __ PRESENTER: JACQUELINE S. GARCIA, MD Assistant Professor of Medicine Harvard Medical School Dana-Farber Cancer Institute Boston, Massachusetts Link to the full program here. https://bit.ly/47z8WCV
In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: __ __ PRESENTERS: ANA MARIN-NIEBLA, MD, PHD Hematology Consultant, Lymphoma Unit Vall d’Hebron Institute of Oncology, Hematology Department Hospital Universitario Vall d’Hebron Barcelona, Spain STEPHAN STILGENBAUER, MD Medical Director Comprehensive Cancer Center Ulm Head, Early Clinical Trials Unit Head, Division of CLL Dept. of Internal Medicine III University Medical Center Ulm University Ulm, Germany Link to full program: HTTPS://BIT.LY/3MNAURI https://bit.ly/3MNaUri
In this episode, Isabelle Ray-Coquard, MD, PhD, and Ana Oaknin, MD, PhD, provide expert insights on new clinical trial data presented at the 2023 ESMO annual congress for endometrial, ovarian, and cervical cancers, including: __ __ PRESENTERS: ANA OAKNIN, MD, PHD Head of Gynaecologic Cancer Programme Department of Medical Oncology Vall d’ Hebron University Hospital Vall d’Hebron Institute of Oncology Barcelona, Spain ISABELLE RAY-COQUARD, MD, PHD President of the Gineco Group Centre Leon Bérard Laboratories RESHAPE Université Claude Bernard Lyon Est Lyon, France This educational activity is supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, and Seagen. Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries: https://bit.ly/424E3Uq
In this episode, Aakash Desai, MD; Narjust Florez, MD; and Paolo Tarantino, MD, discuss the biologic rationale and clinical development of agents targeting HER3 for the treatment of breast and lung cancers. The potential niche for HER3-targeted agents in these treatment landscapes is considered, with consideration of acquired resistance to previous targeted therapies and parallels to other approved antibody–drug conjugates. Their conversation covers clinical trial data from: __ __ PRESENTERS: AAKASH DESAI, MD Affiliation awaiting contract NARJUST FLOREZ, MD Associate Director of The Cancer Care Equity Program Thoracic Medical Oncologist, Dana-Farber Cancer Institute Assistant Professor of Medicine, Harvard Medical School Boston, Massachusetts PAOLO TARANTINO, MD Advanced Research Fellow Breast Oncology Center Dana-Farber Cancer Institute Boston, Massachusetts Content based on an online CME program supported by an independent educational grant from Daiichi Sankyo, Inc. Link to full program: https://bit.ly/45UYsw3
In this episode, Dr Leslie Boyd and Adrienne Moore, a patient advocate and endometrial cancer survivor, discuss how healthcare professionals can partner with Black patients to improve the diagnosis and management of endometrial cancer (EC). Topics include: __ __ PRESENTERS: LESLIE R. BOYD, MD Associate Professor Department of Obstetrics and Gynecology at NYU Grossman School of Medicine Director of Division of Gynecologic Oncology Vice Chair of Gynecology Department of Obstetrics and Gynecology Laura and Isaac Perlmutter Cancer Center New York University Langone Health New York, New York ADRIENNE MOORE, RT President and Board Member Endometrial Cancer Action Network for African-Americans Director of Peer Support, SISTER Study Research Coordinator, Gynecologic Oncology Department of Obstetrics and Gynecology University of Washington School of Medicine Seattle, Washington
In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the ESGO 2023 Congress for cervical, endometrial, and ovarian cancers, including: __ __ PRESENTERS: ALEXANDRA LEARY, MD, PHD Co Director Medical Oncologist and Team Leader Gynecology Translational Research Lab Department of Medicine Gustave Roussy Cancer Center Paris, France DOMENICA LORUSSO, MD, PHD Associate Professor Gynecologic Oncology Department Clinical Research Unit Fondazione Policlinico Gemelli IRCCS Rome, Italy This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab, and Seagen. Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries: https://bit.ly/424E3Uq
In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at SOHO 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: __ __ PRESENTERS: CATHERINE C. COOMBS, MD, MS Associate Clinical Professor Division of Hematology/Oncology, Department of Medicine UCI Health Orange, California TOBY EYRE, MBCHB, MD Honorary Senior Lecturer Hematology and Cancer University of Oxford Consultant Hematologist Department of Hematology Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust Oxford, United Kingdom
In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of: __ __ PRESENTERS: CATHERINE C. COOMBS, MD, MS Associate Clinical Professor Division of Hematology/Oncology, Department of Medicine UCI Health Orange, California TOBY EYRE, MBCHB, MD Honorary Senior Lecturer Hematology and Cancer University of Oxford Consultant Hematologist Department of Hematology Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust Oxford, United Kingdom
In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of: __ __ Presenters: CATHERINE C. COOMBS, MD, MS Associate Clinical Professor Division of Hematology/Oncology, Department of Medicine UCI Health Orange, California TOBY EYRE, MBCHB, MD Honorary Senior Lecturer Hematology and Cancer University of Oxford Consultant Hematologist Department of Hematology Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust Oxford, United Kingdom
In this episode, Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the 2023 ASCO Annual Meeting for cervical, endometrial, and ovarian cancers, including: __ __ PRESENTERS: Kathleen Moore, MD, MS Associate Director, Clinical Research Department of Gynecologic Oncology Stephenson Cancer Center, University of Oklahoma Oklahoma City, Oklahoma Nicoletta Colombo, MD, PhD Associate Professor of Obstetrics and Gynecology European Institute of Oncology University of Milan-Bicocca Milan, Italy Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp., Novocure Inc., and Seagen Inc. Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries: BIT.LY/43Q5CBI https://clinicaloptions.com/CE-CME-program/oncology/key-findings-and-expert-recommendations-in-gynecologic-malignancies-independent-2023-conferencecongress-coverage/17217
In this episode, David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, provide expert insights on practice-changing data and other new findings presented at SGO 2023 in endometrial, cervical, and ovarian cancers, including: __ __ PRESENTERS: DAVID SCOTT MILLER, MD, FACOG, FACS Amy and Vernon E. Faulconer Distinguished Chair in Medical Science Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics & Gynecology Fred F. Florence Bioinformation Center University of Texas Southwestern Medical Center Medical Director of Gynecologic Oncology Chair, Cancer Committee Parkland Health & Hospital System Dallas, Texas LINDA DUSKA, MD, MPH Gynecologic Oncologist Department of OB GYN/Gynecologic Oncology University of Virginia School of Medicine Charlottesville, Virginia Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure Inc., and Seagen Inc. Link to full program: bit.ly/424E3Uq http://www.clinicaloptions.com/GYNCoverage2023Program
In this episode, Suzanne Lentzsch, MD, Ph.D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of: __ __ Presenters: SUZANNE LENTZSCH, MD, PHD Professor of Medicine Division of Hematology/Oncology Director, Multiple Myeloma and Amyloidosis Program Columbia University Medical Center New York, New York JOSEPH MIKHAEL, MD, MED, FRCPC, FACP Professor Applied Cancer Research and Drug Discovery Translational Genomics Research Institute Phoenix, Arizona Chief Medical Officer International Myeloma Foundation HonorHealth Research Institute Scottsdale, Arizona Provided by Clinical Care Options, LLC in partnership with Smart Patients. Content supported by educational grants from AbbVie; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; and Regeneron Pharmaceuticals, Inc. Link to full program: bit.ly/41YEOO6 https://www.clinicaloptions.com/MyelomaSSTprogram
In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including: __ __ PRESENTERS: JOHN MASCARENHAS, MD Professor of Medicine Icahn School of Medicine at Mount Sinai Director, Adult Leukemia Program Leader, Myeloproliferative Disorders Clinical Research Program Division of Hematology/Oncology Tisch Cancer Institute New York, New York RUBEN A. MESA, MD, FACP Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center Enterprise Senior Vice President, Atrium Health President, Enterprise Cancer Service Line Vice Dean for Cancer Programs, Wake Forest University School of Medicine Professor of Medicine, Wake Forest University School of Medicine Winston-Salem, North Carolina
In this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of: __ __ Presenters: BANU ARUN, MD Professor, Breast Medical Oncology Director, Clinical Cancer Genetics University of Texas MD Anderson Cancer Center Houston, Texas ALLISON BUTTS, PHARMD, BCOP Pharmacist Manager, Oncology Director, PGY2 Oncology Residency Program UK HealthCare Assistant Adjunct Professor UK College of Pharmacy Lexington, Kentucky MARISSA MARTI-SMITH, MSN, APRN, AGNP-C, AOCNP Nurse Practitioner Breast Oncology Texas Oncology Baylor Sammons Cancer Center Dallas, Texas Content supported by educational grants from AstraZeneca and Merck Sharp & Dohme Corp. Link to full program: https://bit.ly/42VeUMM
In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including: __ __ PRESENTERS: SAMUEL KLEMPNER, MD Associate Professor Department of Medicine Division of Hematology-Oncology Mass General Cancer Center Harvard Medical School Boston, Massachusetts GREGORY BOTTA, MD, PHD Clinical Professor of Medicine Department of Medicine Division of Hematology & Oncology University of California San Diego La Jolla, California Content for this program was supported by educational grants from Astellas and Bristol Myers Squibb. Link to the full program, including a CME-certified text module, downloadable slideset, and ClinicalThought (): bit.ly/3lQxPrq http://www.clinicaloptions.com/ClaudinGastric2023Program
In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. The topics covered include: __ __ Presenters: PRITHVIRAJ BOSE, MD Division of Cancer Medicine Department of Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas ANDREW KUYKENDALL, MD Department of Oncologic Sciences University of South Florida Malignant Hematology H. Lee Moffitt Cancer Center Tampa, Florida Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp. Link to the full program, including downloadable slides and an on-demand webcast from the live event: bit.ly/3XF3cSF https://clinicaloptions.com/CE-CME-program/oncology/mpn-treatment/100006020
In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia. Topics discussed include: __ __ PRESENTERS: DANIEL J. DEANGELO, MD, PHD Department of Medicine Harvard Medical School Department of Medical Oncology Division of Hematologic Malignancies Dana‐Farber Cancer Institute Boston, Massachusetts EMILY CURRAN, MD Division of Hematology/Oncology University of Cincinnati Cancer Institute Cincinnati, Ohio KJELD SCHMIEGELOW, MD, DMSCI Department of Pediatric Oncology Righospitalet University Hospital Copenhagen, Denmark Content based on an online CME program supported by an independent educational grant from Jazz Pharmaceuticals. Link to full program: http://bit.ly/3YXkLyj
In this podcast episode, Steven M. Horwitz, MD; Pamela B. Allen, MD, MSc; and Kerry Savage, MD, MSc, answer questions from an audience of healthcare professionals on topics related to the management of T-cell lymphomas, including: __ __ Presenters: STEVEN M. HORWITZ MD Member, Memorial Sloan Kettering Cancer Center Attending Physician, Memorial Hospital Professor of Medicine, Weill Cornell Medical College New York, New York PAMELA B. ALLEN, MD, MSC Assistant Professor Department of Hematology/Oncology Emory University, Winship Cancer Institute The Emory Clinic Atlanta, Georgia KERRY SAVAGE MD, MSC Professor of Medicine University of British Columbia Medical Oncologist Division of Medical Oncology BC Cancer Vancouver, British Columbia, Canada Content for this program was supported by educational grants from Daiichi Sankyo; Kyowa Kirin, Inc.; and Seagen Inc. Link to the full program, including downloadable slides, expert commentary, and an on-demand webcast: bit.ly/3ItqEOd https://clinicaloptions.com/CE-CME-program/oncology/tcl:-treatment-advances/100001783
In this podcast, Rami Komrokji, MD; María Díez Campelo, MD, PhD; and Amer Zeidan, MBBS, MHS answer questions from an audience of healthcare professionals on topics related to personalized management of myelodysplastic syndromes including: __ __ Presenters: RAMI KOMROKJI, MD Professor Department of Oncologic Sciences University of South Florida Vice Chair Malignant Hematology Department Moffitt Cancer Center Tampa, Florida María Díez Campelo, MD, PhD Associate Professor Department of Medicine School of Medicine University of Salamanca Hematologist Department of Hematology University Hospital of Salamanca Salamanca, Spain AMER ZEIDAN, MBBS, MHS Associate Professor, Internal Medicine Hematology Leader, Leukemia and Myeloid Disease Aligned Research Team (DART) Director, Hematology Early Therapeutics Research Yale Cancer Center and Smilow Cancer Hospital Yale University School of Medicine New Haven, Connecticut Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast: http://bit.ly/3YXgKK3
In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including: __ __ PRESENTERS: MARK PEGRAM, MD Medical Oncology Stanford University Palo Alto, California SARA TOLANEY, MD, MPH Division of Breast Oncology Harvard Medical School Division of Breast Oncology Breast Oncology Program Dana-Farber Cancer Institute Boston, Massachusetts Content based on an online CME/CE/CPE program supported by educational grants from Gilead Sciences, Inc. Link to full program: http://bit.ly/3iQzDz5
In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include: __ __ Presenters: RAAJIT RAMPAL, MD, PHD Leukemia Service Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York BRADY L. STEIN, MD, MHS Department of Hematology/Oncology Northwestern University Feinberg School of Medicine Chicago, Illinois Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp. Link to the full program, including downloadable slides and an on-demand webcast from the live event: https://bit.ly/3X3x6jX
In this episode, David Kaplan, MD, MSc, and Tamar Taddei, MD, discuss which patients should be screened for hepatocellular carcinoma, current surveillance recommendations, barriers to implementation, emerging biomarkers in development, and unmet needs in hepatocellular carcinoma surveillance. PRESENTERS: DAVID E. KAPLAN, MD, MSC Perelman School of Medicine Hepatology Section Division of Gastroenterology and Hepatology University of Pennsylvania Director of Hepatology Corporal Michael J. Crescenz VA Medical Center Philadelphia, Pennsylvania TAMAR TADDEI, MD Section of Digestive Diseases Department of Internal Medicine Yale School of Medicine GI Section VA Connecticut Healthcare System West Haven, Connecticut
In this episode, Zoe Lanham, a woman with high-risk hormone receptor–positive/HER2-negative early breast cancer, discusses the importance of effective communication between patients and their healthcare team, drawing on her personal experience. Presenter: ZOE LANHAM Link to full program: https://bit.ly/3Fukjzk
In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including: • Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer • Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test • Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial • Survival results from phase III ARIEL3: maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer Presenters: ISABELLE RAY-COQUARD, MD, PHD Clinical Science Institute of the Léon Bérard Center Lyon, France IGNACE VERGOTE, MD, PHD University Hospitals Leuven Leuven, Belgium Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp. Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: https://bit.ly/3SSSqpN
